Medical Cannabis for Cancer Patients in the UK

A cancer diagnosis is one of the most challenging experiences a person can face. For many patients undergoing chemotherapy, the treatment itself can be as debilitating as the disease. Severe nausea, vomiting, pain, and loss of appetite are common and persistent side effects. Cannabis-based medicines have emerged as a clinically supported option to help manage these side effects, and in the UK, access through legitimate medical channels has expanded significantly since 2018.

This guide explains what the evidence says, which medicines are available, and how UK cancer patients can access cannabis-based treatment through a licensed prescriber.

How Medical Cannabis Helps Cancer Patients

Cannabis-based medicines interact with the endocannabinoid system (ECS), a network of receptors (CB1 and CB2) involved in regulating pain, nausea, appetite, mood, and immune function. In cancer patients, this interaction can produce several clinically relevant effects:

• Anti-emetic action: THC activates CB1 receptors in the brainstem, suppressing the vomiting reflex triggered by chemotherapy drugs.
• Appetite stimulation: Cannabinoids can counteract cachexia (cancer-related weight loss and muscle wasting), helping patients maintain nutritional intake during treatment.
• Analgesic effects: Both THC and CBD modulate pain signalling pathways, offering adjunct relief for cancer-related pain not adequately controlled by conventional analgesics.
• Anxiolytic and sleep support: CBD-dominant formulations may help reduce treatment-related anxiety and improve sleep quality, factors that significantly affect quality of life and immune resilience.

Cannabis-based medicines are used as adjunct therapy. They support, rather than replace, oncological treatment. No licensed cannabis-based medicine in the UK is indicated as an anti-tumour agent.

Chemotherapy-Induced Nausea and Vomiting (CINV): The Evidence

Chemotherapy-induced nausea and vomiting (CINV) affects up to 80% of patients receiving emetogenic chemotherapy regimens, even with standard anti-emetic prophylaxis. Breakthrough CINV, episodes occurring despite preventive medication, remains a significant unmet clinical need.

The evidence base for cannabinoids in CINV is among the most mature in the field:

1. A Cochrane systematic review analysed 23 randomised controlled trials involving 1,326 participants and found that cannabinoids were more effective than placebo and, in some comparisons, comparable to conventional anti-emetics for reducing CINV.
2. The Parker et al. RCT demonstrated that nabilone (a synthetic cannabinoid) significantly reduced nausea severity and vomiting frequency versus prochlorperazine in patients receiving highly emetogenic chemotherapy.
3. A meta-analysis in JAMA Oncology found that THC-containing medicines produced a clinically meaningful reduction in nausea in patients with refractory CINV, with an acceptable tolerability profile when titrated appropriately.
4. NICE guidance (NG144) acknowledges that clinicians may consider cannabis-based medicinal products for CINV where standard treatment has failed.

Real-world data from Sapphire Medical Clinics, the largest medical cannabis registry in the UK, reports that a substantial proportion of oncology patients experience meaningful reductions in nausea following initiation of cannabis-based treatment.

Cannabis-Based Medicines Approved in the UK for Cancer Care

Under the Misuse of Drugs (Amendment) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018, specialist doctors can prescribe cannabis-based medicinal products (CBMPs) on a named-patient basis. The following medicines are in active clinical use in UK oncology-adjacent settings:

Nabilone is the only cannabis-based medicine with a full UK marketing authorisation specifically for CINV. All other CBMPs, including EU-GMP certified dried flower products, are prescribed on a named-patient, unlicensed basis via a specialist prescriber.

For information on specific EU-GMP certified products available through our network, visit our product strain library.

How to Access Medical Cannabis as a Cancer Patient in the UK

The NHS does not routinely commission cannabis-based medicines for most conditions, meaning the majority of UK cancer patients access CBMPs through private specialist clinics. The legal pathway is clear and well-established:

1. Obtain a referral or self-refer to a specialist clinic registered to prescribe Schedule 2 controlled drugs. Your oncologist, GP, or palliative care team may refer you, or you can approach a specialist clinic directly.
2. Initial consultation with a specialist doctor, typically an oncologist, pain specialist, or palliative care consultant. The prescriber will review your diagnosis, current treatment regimen, and symptom burden before recommending a CBMP.
3. Prescription issued on a named-patient basis. The prescription is fulfilled by a specialist pharmacy registered with the MHRA to dispense Schedule 2 controlled drugs.
4. Follow-up and titration. Dosing is individualised. Patients are typically started on a low dose and titrated upward based on clinical response and tolerability.

To find a specialist prescriber in your area, use our doctor finder tool. To explore the full process from symptom assessment to prescription, visit our UK patient guide.

What UK Oncologists Say About Cannabis-Based Medicines

Clinician attitudes towards cannabis-based medicines in oncology have shifted substantially. A survey published in BMJ Supportive & Palliative Care found that over 60% of UK palliative care physicians reported patients raising the topic of cannabis-based treatment, and a significant minority had either prescribed or referred patients for specialist prescribing.

Key clinical perspectives include:

• Integration with standard oncology care: CBMPs should always be used alongside established CINV protocols, including 5-HT3 antagonists, NK1 receptor antagonists, and dexamethasone, not as a replacement.
• Patient selection matters: Patients with refractory CINV, neuropathic pain, or significant anxiety are most likely to benefit. A structured baseline assessment improves prescribing decisions.
• Drug interaction awareness: CBD is metabolised via CYP450 pathways and can interact with certain chemotherapy agents, including tamoxifen and some taxanes. A specialist prescriber will review these interactions prior to prescribing.
• EU-GMP quality assurance: Pharmaceutical-grade products certified to EU Good Manufacturing Practice standards provide the consistency and traceability necessary for oncology patients whose immune systems may be compromised.

For clinical resources, product formulary data, and partnership enquiries, our clinician hub provides direct access to our medical affairs team.

Risks and Considerations for Cancer Patients

Cannabis-based medicines carry a favourable safety profile relative to many pharmacological alternatives, but cancer patients represent a clinically complex population. The following considerations are essential:

• Immunosuppression: Oil and capsule formulations are generally preferred in patients receiving myelosuppressive chemotherapy, as inhaled products carry a theoretical respiratory infection risk in immunocompromised patients.
• Cognitive effects: THC-containing products can cause short-term cognitive impairment, dizziness, and postural hypotension, particularly during initial dose titration. Patients should be advised not to drive until their response is established.
• Drug-drug interactions: CBD can inhibit CYP3A4 and CYP2C9 enzymes, affecting the metabolism of certain chemotherapy drugs, anticoagulants (including warfarin), and anticonvulsants. A full medication review is mandatory before prescribing.
• Psychiatric history: A personal or family history of psychosis is a relative contraindication for high-THC preparations. CBD-dominant formulations may be more appropriate in these patients.
• Pregnancy and fertility: Cannabis-based medicines are contraindicated in pregnancy. Patients of childbearing potential should discuss the implications with their oncologist and prescribing physician.
• Product quality: Only EU-GMP certified products should be considered for oncology patients. Non-pharmaceutical-grade cannabis carries unknown contaminant profiles that are inappropriate in medically vulnerable populations.

These considerations underline the importance of obtaining cannabis-based treatment through a regulated specialist clinic, not through informal or unregulated channels.

Summary: Key Takeaways for Cancer Patients

• Cannabis-based medicines, particularly nabilone and EU-GMP certified THC-containing products, have a meaningful evidence base for managing CINV.
• In the UK, CBMPs for cancer care are accessed through specialist private clinics. The NHS does not routinely fund these treatments for oncology indications.
• Drug-drug interaction review, EU-GMP quality assurance, and individualised titration are non-negotiable in cancer patients.
• Specialist prescribers, not GPs, issue CBMP prescriptions. Referral is straightforward and can be self-initiated.
• NICE guidelines support consideration of cannabinoids for refractory CINV where conventional anti-emetics have failed.

Medically reviewed by the Cannamedical Britannia Clinical Team, May 2026.

References: NICE NG144 (2021); Cochrane Review: Cannabinoids for nausea and vomiting in adults with cancer (2015); Parker LA et al., Nabilone for CINV; JAMA Oncology meta-analysis on cannabinoids and CINV; BMJ Supportive & Palliative Care: UK clinician survey; NHS England Specialised Commissioning guidance on CBMPs.